Sacituzumab Govitecan Shows No Significant OS Improvement in Treated Advanced/Metastatic NSCLC

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. For patients with advanced or metastatic NSCLC, especially those whose disease progresses after platinum-based chemotherapy and immunotherapy, existing treatment options are still limited. There have been innovations in treatment methods, but the survival of patients is still not ideal. Against this background, many studies are devoted to exploring new treatment methods, one of which is antibody-drug conjugates (ADCs) - a new type of therapy that combines the targeting of antibodies with the cytotoxicity of chemotherapy drugs. This article will summarize the main findings of the EVOKE-01 study and explore the potential of sacituzummab govitecan, a new ADC, in the treatment of NSCLC.

Study Background and Design

The EVOKE-01 study is a global, randomized, open-label phase III clinical trial designed to evaluate the efficacy and safety of sacituzummab govitecan compared with the traditional chemotherapy drug docetaxel in the treatment of patients with advanced or metastatic NSCLC. The primary endpoint of the study was overall survival (OS), and secondary endpoints included progression-free survival (PFS), objective response rate (ORR), patient self-reported symptom assessment, and safety.

A total of 603 patients were enrolled in the study who had progressed after platinum chemotherapy and immune checkpoint inhibitors (PD-(L)1). The study randomly divided patients into two groups to receive sacituzummab govitecan (10 mg/kg intravenously on days 1 and 8 every 21 days) or docetaxel (75 mg/m2 intravenously on day 1 every 21 days). The study was stratified by different histological types, the best response of patients to the last PD-(L)1 treatment, and whether they had received treatment targeting actionable genetic mutations.

Main findings

The results of the EVOKE-01 study showed that sacituzummab govitecan failed to achieve a statistically significant advantage in overall survival, but showed some improvement in survival numerically. Specifically, the median OS in the sacituzummab govitecan group was 11.1 months, while it was 9.8 months in the docetaxel group, and the risk of death was reduced by 16% (HR 0.84, 95% CI 0.68 to 1.04, one-sided p = 0.0534). This survival advantage was consistent across different histological types (squamous and non-squamous histology).

In terms of progression-free survival (PFS), there was little difference between the two groups (4.1 months vs. 3.9 months, HR 0.92, 95% CI 0.77 to 1.11), but in the patient's self-reported symptom assessment, the sacituzummab govitecan group had a longer time to symptom worsening, indicating that the drug has potential benefits for patients' quality of life.

Safety and Tolerability

In terms of safety, sacituzummab govitecan showed good tolerability, with a lower incidence of high-grade adverse events and a lower proportion of discontinuations or dose reductions due to treatment-related adverse events (TRAEs) than the docetaxel group. Specific data showed that 6.8% of patients in the sacituzummab govitecan group discontinued treatment due to TRAEs, while the proportion in the docetaxel group was 14.2%. In terms of treatment-related deaths, the proportions of the two groups were similar (1.4% and 1.0%, respectively).

These results show that sacituzummab govitecan not only has encouraging efficacy in the treatment of patients with advanced NSCLC, but also has good safety, and no new safety signals have emerged.

Research limitations and prospects

The results of the EVOKE-01 study showed the potential of sacituzummab govitecan in the treatment of advanced NSCLC, but there are also some limitations. The study failed to achieve statistical significance in overall survival (OS) and progression-free survival (PFS), which limits the clinical application prospects of sacituzummab govitecan to a certain extent. Secondary endpoints of the study, such as objective response rate (ORR), also did not show significant improvement, further weakening the overall efficacy impression of the drug.

The study authors and other experts in the field remain cautiously optimistic about the future use of sacituzummab govitecan in the treatment of NSCLC. Currently, studies are underway to combine sacituzummab govitecan with other treatments, such as the EVOKE-02 and EVOKE-03 studies, which will evaluate its combination with pembrolizumab (immunotherapy drug). By exploring these combination therapies, researchers hope to further improve the efficacy of sacituzummab govitecan in the treatment of NSCLC and overcome the limitations of monotherapy.

Overall, the EVOKE-01 study showed that sacituzummab govitecan has certain efficacy advantages in treating patients with advanced or metastatic NSCLC, especially when compared with the existing standard of care docetaxel. The study failed to meet all expected clinical endpoints, but its performance in terms of survival and safety remains interesting. Future studies will further evaluate the potential of the drug in combination with other therapies to provide more effective treatment options for NSCLC patients.